Newsletter Tool

To view this email as a web page, click here

Today's Rundown

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports
Nursing home organizations warn governors of 'imminent' COVID-19 outbreaks
Bolstered by immunology and oncology, J&J’s pharma business holds up under COVID-19 pressure
Hospitals' inpatient volumes rebounded faster than emergency departments: TransUnion
Anthem, CloudMedx launch digital tool to help employers, public health officials track impact of COVID-19
Poll: 75% of public supports more hospital COVID-19 relief funding as Congress ponders next move
Healthcare roundup: 3.3M seniors live with school-aged children creating public health hurdle
Biopharma roundup: Sinopharm doses world's first phase 3 vaccine patients; Moderna, J&J, Sanofi and more in EU supply talks

Featured Story

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports

By Kyle Blankenship

With COVID-19 vaccine players speeding their way through early testing, governments around the world are looking to put deals in place to secure supply of a possible winner for their own citizens. Drugmakers like AstraZeneca may already be ahead of the pack, but other companies are now taking a seat at the negotiating table.

Nursing home organizations warn governors of 'imminent' COVID-19 outbreaks

By Tina Reed

In a letter from the American Health Care Association and the National Center for Assisted Living, officials warned the spikes in cases across the U.S.—combined with ongoing shortages of personal protective equipment and testing delays—will make it difficult to protect residents from the virus.

Bolstered by immunology and oncology, J&J’s pharma business holds up under COVID-19 pressure

By Eric Sagonowsky

With Johnson & Johnson being the first drugmaker to report earnings each quarter, market watchers have eagerly looked to the drugmaker's performance amid the pandemic to see how other biopharma players might fare. And in the second quarter, J&J posted growth in pharma despite COVID-associated challenges.

Hospitals' inpatient volumes rebounded faster than emergency departments: TransUnion

By Tina Reed

The steep losses in volumes experienced by hospitals in the early days of the COVID-19 pandemic began to reverse in June, according to a newly released book from TransUnion Healthcare.

Anthem, CloudMedx launch digital tool to help employers, public health officials track impact of COVID-19

By Paige Minemyer

Anthem has launched a digital tool that aims to allow public health officials and other health and community leaders to track and predict the impacts of COVID-19.

Poll: 75% of public supports more hospital COVID-19 relief funding as Congress ponders next move

By Robert King

A new poll sponsored by the hospital industry finds widespread support for another round of stimulus funding to help hospitals weather the COVID-19 financial crisis.

Healthcare roundup: 3.3M seniors live with school-aged children creating public health hurdle

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: Sinopharm doses world's first phase 3 vaccine patients; Moderna, J&J, Sanofi and more in EU supply talks

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

European officials are working on vaccine supply deals with Moderna, Johnson & Johnson, Sanofi and more, as J&J talks distribution with Japan and the Bill & Melinda Gates Foundation. Fosun got the OK to run trials on its shot, and Sinopharm dosed the first patients in its phase 3 trial, the first to officially launch worldwide.

COVID-19 Tracker